

## References

### I-186

1. Hayes Inc. Prognosis Overview. Trogarzo (Ibalizumab-uiyk) for Multidrug Resistant HIV-1. March 2018. Accessed April 25, 2018.
2. The American Journal of Health-System Pharmacy. FDA approves novel biologic for resistant HIV infection. *Am J Health-System Pharm.* 2018;75(8):505-506.
3. Trogarzo (Ibalizumab-uiyk) injection, for intravenous use [package insert]. Theratechnologies Inc. Montreal, Quebec Canada. Revised 04/2020.
4. Micromedex®Solutions Compendia. 2020. Ibalizumab.
5. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Ibalizumab. 2020.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Updated December 18, 2019. Accessed 10/9/2020.
7. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. *N Engl J Med.* 2018;379:645-654.
8. Beccari MV, Mogle BT, Sidman EF, et al. Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. *Am Soc Microbiol.* 2019;63(6):110-119.
9. Ibalizumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 25, 2019.
10. Panel on Treatment of Pregnant Women with HIV infection and Prevention of Perinatal Transmission. Department of Health and Human Services. Updated April 14, 2020. Accessed 10/9/2020.